Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery
Authors:
- 26 November 2014
- journal article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 16 (3) , 610-622
Abstract
The objective of this study was to develop a clear, aqueous rapamycin-loaded mixed nanomicellar formulations (MNFs) for the back-of-the-eye delivery. MNF of rapamycin (0.2%) was prepared with vitamin E tocopherol polyethylene glycol succinate (TPGS) (Vit E TPGS) and octoxynol-40 (Oc-40) as polymeric matrix. MNF was characterized by various parameters such as size, charge, shape, and viscosity. Proton nuclear magnetic resonance (1H NMR) was used to identify unentrapped rapamycin in MNF. Cytotoxicity was evaluated in human retinal pigment epithelial (D407) and rabbit primary corneal epithelial cells (rPCECs). In vivo posterior ocular rapamycin distribution studies were conducted in male New Zealand white rabbits. The optimized MNF has excellent rapamycin entrapment and loading efficiency. The average size of MNF was 10.98 ± 0.089 and 10.84 ± 0.11 nm for blank and rapamycin-loaded MNF, respectively. TEM analysis revealed that nanomicelles are spherical in shape. Absence of free rapamycin in the MNF was confirmed by 1H NMR studies. Neither placebo nor rapamycin-loaded MNF produced cytotoxicity on D407 and rPCECs indicating formulations are tolerable. In vivo studies demonstrated a very high rapamycin concentration in retina-choroid (362.35 ± 56.17 ng/g tissue). No drug was identified in the vitreous humor indicating the sequestration of rapamycin in lipoidal retinal tissues. In summary, a clear, aqueous MNF comprising of Vit E TPGS and Oc-40 loaded with rapamycin was successfully developed. Back-of-the-eye tissue distribution studies demonstrated a very high rapamycin levels in retina-choroid (place of drug action) with a negligible drug partitioning into vitreous humor.Keywords
This publication has 45 references indexed in Scilit:
- Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyJournal of Ophthalmic Inflammation and Infection, 2013
- Iontophoretic transport of charged macromolecules across human scleraInternational Journal of Pharmaceutics, 2010
- Interaction of Ocular Hypotensive Agents (PGF2α Analogs—Bimatoprost, Latanoprost, and Travoprost) With MDR Efflux Pumps on the Rabbit CorneaJournal of Ocular Pharmacology and Therapeutics, 2009
- Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE‐induced sprouting angiogenesis in vitroFEBS Letters, 2008
- Autoimmunity in the immune privileged eye: pathogenic and regulatory T cellsImmunologic Research, 2008
- Regulation of VEGF mRNA expression and protein secretion by TGF-β2 in human retinal pigment epithelial cellsExperimental Eye Research, 2007
- Hydrotropic Polymeric Micelles for Enhanced Paclitaxel Solubility: In Vitro and In Vivo CharacterizationBiomacromolecules, 2006
- Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine–sirolimus interactionKidney International, 2006
- Chronic Non-Infectious Uveitis in the ElderlyDrugs & Aging, 2006
- Tonicity of human tear fluid sampled from the cul-de-sac.British Journal of Ophthalmology, 1989